![](/static/media/logo.jpg)
An International Publisher for Academic and Scientific Journals
Author Login
Scholars Journal of Medical Case Reports | Volume-11 | Issue-10
Efficacy of Low-Dose Nivolumab in Multiple Cancer Types
Dr. Ali Asgar Chowdhury
Published: Oct. 10, 2023 |
150
118
DOI: 10.36347/sjmcr.2023.v11i10.019
Pages: 1795-1797
Downloads
Abstract
Introduction: Cancer is the uncontrolled growth and development of cells in the body, and is one of the foremost reasons of deaths throughout the world. Immunotherapy is a broad category of cancer therapies that triggers the body's immune system to fight cancer cells. Nivolumab, a monoclonal antibody, is used an immunotherapy drug that binds to the Programmed Cell Death protein (PD-1) to help immune cells kill cancer cells better and is used to treat many different types of cancer. This study is about two cancer patients, one being a case of Squamous Cell Carcinoma of the Right Lung, another being a case of metastatic Stage IV Renal Cell Carcinoma. They were treated with low-dose Nivolumab and resulted in remission of the malignancy without any significant complications. Case Presentation: The current study was conducted with 2 Bangladeshi male patients. The first patient, case of Carcinoma Lung, 55 years old, and the second patient, Renal Cell Carcinoma, 57 years old. They were treated with 6 cycles of Nivolumab at 40 mg dose for immunotherapy regimen. Both of them are clinically stable and no complications have been detected. Conclusion: Treatment with Nivolumab in such fatal cancers has demonstrated remarkable clinical response with significant remission of the disease. In addition, adverse effects are minimal compared to previous drug regimens.